Thompson Siegel & Walmsley LLC Rocket Pharmaceuticals, Inc. Transaction History
Thompson Siegel & Walmsley LLC
- $6.43 Billion
- Q4 2024
A detailed history of Thompson Siegel & Walmsley LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Thompson Siegel & Walmsley LLC holds 12,747 shares of RCKT stock, worth $133,461. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,747Holding current value
$133,461% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RCKT
# of Institutions
244Shares Held
108MCall Options Held
262KPut Options Held
159K-
Rtw Investments, LP New York, NY17.7MShares$185 Million3.63% of portfolio
-
Wellington Management Group LLP Boston, MA14MShares$147 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.58MShares$68.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$64.8 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx5.2MShares$54.4 Million1.26% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $792M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...